# Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

> **NCT00081926** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 112 (—)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Gleevec

## Key facts

- **NCT ID:** NCT00081926
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 112 (—)
- **Last updated:** 2009-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00081926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00081926, "Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00081926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*